Table 1 Baseline Characteristics
From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Characteristics | TACE-alone group (N = 51) (No, %; Mean ± SD) | TACE-camrelizumab group (N = 20) (No, %; Mean ± SD) | P value |
|---|---|---|---|
Gender | Â | Â | 0.223 |
 Male | 43 (84.3%) | 19 (95%) |  |
 Female | 8 (15.7%) | 1 (5%) |  |
Age (years) | 52.5 ± 10.7 | 50.3 ± 11.3 | 0.045 |
ECOG performance | Â | Â | 0.769 |
 0 | 21(41.2%) | 9(45%) |  |
 1 | 30(58.8%) | 11(55%) |  |
Hepatitis | Â | Â | 0.428 |
 Hepatitis B | 39 (76.5%) | 17 (85%) |  |
 Other | 12 (23.5%) | 3 (15%) |  |
Child–Pugh class |  |  | 0.101 |
 A | 49 (96.1%) | 17 (85%) |  |
 B | 2 (3.9%) | 3 (15%) |  |
BCLC stage | Â | Â | 0.113 |
 B | 14(27.5%) | 2 (10%) |  |
 C | 37(72.5%) | 18 (90%) |  |
TB (µmol/L) | 19.08 ± 6.78 | 20.56 ± 10.6 | 0.486 |
Albumin (g/L) | 37.3 ± 5.5 | 35.8 ± 3.00 | 0.064 |
PT(s) | 14.1 ± 1.4 | 13.9 ± 1.1 | 0.600 |
AST (µmol/L) | 39.2 ± 44.0 | 55.4 ± 23.2 | 0.124 |
ALT (µmol/L) | 33.8 ± 21.0 | 39.5 ± 17.0 | 0.285 |
PLR | 142.6 ± 75.9 | 157 ± 83.0 | 0.477 |
NLR | 3.9 ± 1.8 | 3.5 ± 1.1 | 0.381 |
Tumor size (cm) | 3.3 ± 2.3 | 4.1 ± 2.6 | 0.99 |
Tumor number | Â | Â | 0.756 |
  = 1 | 11 (21.6%) | 5 (25%) |  |
  ≥ 2 | 40 (78.4%) | 15(75%) |  |
α-Fetoprotein level |  |  | 0.280 |
  > 400 ng/mL | 16(31.4%) | 9(45%) |  |
  ≤ 400 ng/ml | 35(68.6%) | 11(55%) |  |
Ascites | Â | Â | 0.254 |
 Absent | 44(86.3%) | 15(75%) |  |
 Present | 7(13.7%) | 5(25%) |  |
Portal vein invasion | Â | Â | 0.531 |
 Yes | 14(27.5%) | 7(35.0%) |  |
 No | 37(72.5%) | 13(65.0%) |  |
Extrahepatic metastasis | Â | Â | 0.994 |
 Yes | 28(54.9%) | 11(55.0%) |  |
 No | 23(45.1%) | 9(45.0%) |  |